noimidazoles (NAIMs) have also been reported to inhibit replication of the WT virus as well as an HIV-1 strain that contained both the K103N and Y181C mutations (10) (Fig. 1) .
Earlier works in our laboratory have identified various imidazole derivatives exhibiting broad-spectrum chemotherapeutic properties (11, 12) . In continuation of our effort to develop imidazoles as broad-spectrum chemotherapeutic agents and encouraged by the work of de Martino et al. (9) , we undertook the present study to synthesize and evaluate novel imidazoles and nitroimidazoles that could suppress HIV replication and also inhibit opportunistic microorganisms. Docking studies with HIV-1 RT (PDB ID 1FK9) were also performed in order to investigate the binding pattern of the compounds showing inhibitory activity on HIV-1 RT.
EXPERIMENTAL
Melting points are uncorrected and were measured on an IEC Precision melting point apparatus (Indian Equipment Corporation, India). Elemental analyses were performed on a Vario EL III M/s Elementar C, H, N, S, O analyzer (Germany). The 1 H NMR spectra were measured with a Bruker Avance digital spectrophtometer (Switzerland) (300 MHz) in DMSO-d6 and chemical shifts were assigned in ä ppm. The FAB mass spectra were recorded on a JEOL SX 102/DA-6000 mass spectrometer/data system using argon/xenon (6 kV, 10 mA) as the FAB gas (Japan) . Metronidazole was obtained from ARISTO Pharmaceuticals Pvt. Ltd. (India) and 2-methylimidazole was obtained from Ozone International, India.
1-(3'-Chloroacetonyl)-2-methyl-4-nitroimidazole (1), 2-[chloro(phenyl)methyl]thiophene (3a), 3-(2-chloro-2-phenylethyl)thiophene (3b), 2-[chloro(phenyl)methyl]pyrazine (3c) and 2-[chloro(phenyl)methyl]benzenethiol (3d) were prepared according to previously reported procedures (13) . w-Chloroalkanamides (6) were also prepared according to a previously reported method (14) .
Physicochemical and spectral data for the synthesized compounds are given in Tables I and II. Synthetic routes are presented in Schemes 1-3. 
General procedure. -A mixture of 1 (0.92 mmol), triethylamine (1.43 mmol) and appropriate aromatic amines (0.92 mmol) in 2 mL N,N-dimethylformamide (DMF) was refluxed for 5 h with stirring. After cooling, 20 mL of cold water was added to the reaction mixture. The precipitate obtained was filtered, air-dried and recrystallized from ethyl acetate. (13) . -A mixture of 2-[chloro(phenyl)methyl]thiophene (3a), triethylamine (0.75 mmol) and 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole (4) (0.19 mol) in 2 mL anhydrous DMF was stirred at 50°C overnight. After cooling, the mixture was diluted with 15 mL of water and extracted with ethyl acetate (2´30 mL). The organic layer was then dried over anhydrous sodium sulphate. The solvent was then evaporated to yield a precipitate, which was then recrystallized from methanol/ethyl acetate (2:8) mixture.
2-Methyl-5-nitro-1-{2-[phenyl(thiophen-2-yl)methoxy]ethyl}-1H-imidazole (5a)
Analogously, 2-methyl-
-To a solution of appropriate 2-chloro-N-(3-hydroxyphenyl)alkanamide (6) (0.7 mmol) in 2 mL DMF, the substituted imidazole (7) (0.7 mmol) and anhydrous potassium carbonate (0.050 g) were added. The reaction mixture was heated at 60-70°C for 6-8 h with 
Biological assays
Antimicrobial evaluation. -Antimicrobial activity of the synthesized compounds was determined in vitro using the 2-fold serial broth dilution method in duplicates (15) against pathogenic microorganisms Escherichia coli NCIM 2810, Salmonella typhi NCIM 2501 (Gram-negative bacteria), Staphylococcus aureus NCIM 2901 and Bacillus subtilis MTCC 441 (Gram-positive bacteria). Metronidazole was used as the standard. Preparation of the standard and test stock solution was carried out by dissolving metronidazole and each of the synthesized compounds (2a-e, 5a-d and 8a-f) in dimethylsulfoxide (DMSO) to give a concentration of 4 mg mL -1 .
Fresh nutrient broth cultures were prepared by inoculating and incubating the desired microorganism at 37°C for 24 h. These fresh cultures were standardized using the McFarland standard. 0.4 mL of 4 mg mL -1 test stock solution in DMSO was transferred to the first sterile test tube containing 3.6 mL of 1.1x (where x was the single strength concentration of nutrient broth medium) nutrient broth to prepare 400 µg mL -1 as starting dose, and the remaining test tubes 2-9 were serially diluted with double-strength nutrient broth to obtain the desired concentrations of 200, 100, 50, 25, 12.5, 6.25, 3.125 and 1.56 µg mL -1 , respectively. The test tube with no compound but with equal volume of solvent DMSO (10 %) served as solvent control. One test tube with no compound and no vehicle but only with nutrient medium served as a negative control to ensure the growth property of the medium. Finally, to these test tubes (serially diluted test tubes containing the synthesized compound and positive control as metronidazole, solvent control test tubes and the negative control test tube), 0.1 mL suspension of 10 8 cfu mL -1 of the desired microorganism was added and further incubated at 37°C for 24 hours. The lowest concentration, which apparently caused complete inhibition of the growth of test organisms, was considered the MIC value of the test compound and was expressed in µg mL -1 .
Anti-HIV-1 activity. -All the synthesized compounds were evaluated for inhibitory activity on HIV-1 RT using the HIV-1 RT RNA dependent DNA polymerase activity assay. Efavirenz was used as the standard. Fixed time point assays were used to determine HIV-1 RT-associated RNA-dependent DNA polymerase activity, as reported previously (16) . Assays were carried out using poly (rA)-oligo (dT18) as the template/primer (T/P) substrate. Oligo (dT18) primers were synthesized with a biotin label on the 5'-terminus. DNA polymerase reactions were carried out in 50 mmol L -1 Tris-HCl pH 7.5 (37°C), 50 mmol L -1 KCl, 10 mmol L -1 MgCl 2 containing 600 nmol L -1 T/P, 1 mmol L -1 of [ 3 H] TTP, and variable inhibitor concentrations. Reactions were initiated by the addition of 25 nmol L -1 of RT, incubated for 20 min at 37°C and then quenched with 0.5 mol L -1 EDTA. Streptavidin scintillation proximity assay beads (GE Healthcare, USA) were then added to each reaction, and the extent of radionucleotide incorporation was determined by scintillation spectrometry using a 1450 Microbeta Liquid Scintillation Counter (Perkin Elmer, USA).
Molecular modelling and ligand and protein structure
All computational studies were carried out using the Glide 5.0 (Schrödinger Inc., USA) software package installed in a single machine running on a 3.4 GHz Pentium 4 processor with 1 GB RAM and 160 GB Hard Disk with Red Hat Linux Enterprise version 5.0 as the Operating System. Ligand structures were drawn using the Ligprep utility of Glide. These structures were then geometry optimized by using the Optimized Potentials for Liquid Simulations-2005 (OPLS--2005) force field (17, 18) with the steepest descent followed by truncated Newton conjugate gradient protocol. Partial atomic charges were computed using the OPLS-2005 force field.
The geometry of the non-nucleoside inhibitory binding pocket (NNIBP) of the wild type RT strain was taken from the structure of the HIV-1 RT/EFAVIRENZ complex filed in the RCSB Protein Data Bank (entry code 1FK9). Water molecules were removed from the complex. The protein was optimized for docking using the protein preparation wizard of Schrödinger Inc. Partial atomic charges were assigned according to the Optimized Potentials for Liquid Simulations (OPLS) force field.
Validation of the docking protocol
The most suitable method of evaluating the accuracy of a docking procedure is to determine how closely the lowest energy pose predicted by the scoring function resembles an experimental binding mode as determined by X-ray crystallography. In the present study, the Extra Precision Glide docking procedure was validated by removing efavirenz from the binding site and re-docking it to the NNIBP of HIV-1 RT.
We found very good agreement between the localization of the inhibitor efavirenz upon docking and from the crystal structure (Fig. 2) . The relative mean square deviations (RMSD) between the predicted conformation and the observed X-ray crystallographic conformation of efavirenz equaled 1.026 Å. This indicated the reliability of the docking method in reproducing the experimentally observed binding mode for HIV-1 RT.
RESULTS AND DISCUSSION

Chemistry
Compounds 2a-e were prepared using 1-(3'-chloroacetonyl)-2-methyl-4-nitroimidazole 1 as starting material in the reaction with different primary aromatic amines in the presence of triethylamine (reaction time varied from 4 to 5 h). Spectral data are displayed in Table II . The reaction sequence is given in Scheme 1.
The IR and mass spectra were reported for all the newly synthesized compounds 2a-e while 1 H NMR spectra were assigned for compounds 2c and 2d. In general, infrared spectral data (n, cm -1 ) revealed bands at 3325-3381 (NH), 1600-1656 (C=O), 1500-1543 (N=O) and 1290-1340 (CN). The 1 H NMR spectra of 2c and 2d showed a singlet of one proton at d 8.22 and 8.20 ppm assigned to the proton at the fifth position of the imidazole nucleus, respectively. The peaks at d 6.90-6.51 ppm were assigned to the aromatic protons for compound 2c while the peaks at d 6.638-7.039 ppm were assigned to the aro- (4) in anhydrous dimethyl formamide at 50°C following the procedure of Martino et al. (9) . The reaction sequence is given in Scheme 2.
In general, infrared spectral data revealed bands at 1523-1537 (N=O), 1188-1193 (C-O-C), and 850 cm -1 (C-N). The 1 H NMR spectrum of compounds 5a, 5c and 5d, showed a singlet of 3 protons assigned to imidazole at d 2.45 ppm and a singlet of one proton at d 8.02 ppm assigned to the imidazole nucleus proton at the fifth position. Compounds 5a and 5d showed a triplet of two protons at d 4.37-4.33 ppm and 3.70-3.65 ppm assigned to the N-CH 2 and O-CH 2 group respectively. Similarly compound 5c also showed a triplet of two protons at d 4.37-4.33 and 3.68-3.67 ppm assigned to the N-CH 2 and O-CH 2 groups respectively. Compound 5a also showed a broad singlet at 7.33-7.24 ppm assigned to the aromatic protons. Similarly compounds 5c and 5d showed a multiplet at d 7.4-7.27 ppm assigned to the aromatic protons.
Analogs 8a-8f were synthesized by treating appropriate w-chloroalkanamides 6 with substituted imidazoles 7 under constant stirring in DMF in the presence of potassium carbonate at 60-70°C.
The 1 H NMR spectra of compounds 8a and 8b showed a singlet of one proton at d 10.13 and 9.58 ppm assigned to the proton of the CONH group, respectively. Another singlet of one proton was observed at d 9.95 and 9.43 ppm assigned to the hydroxyl proton attached to the aromatic group for compounds 8a and 8b, respectively. Compounds 8a and 8b also showed multiplets of four protons in the range of d 7.27-7.00 and 7.38-7.12 ppm, respectively, for all the aromatic protons at positions 2, 4, 5, and 6 of the phenyl ring. Compounds 8a and 8b also showed a singlet at d 6.73 ppm assigned to the proton at the 4 th position of the imidazole ring, while another singlet at d 6.97 and 6.83 ppm was observed for the proton at 5 th position of the imidazole ring, respectively, for both compounds. Compound 8a showed a quartet for the proton of CH(CH 3 )CONH at d 4.80 ppm while 8b showed a singlet for two protons of the linker group CH 2 CONH at d 4.66 ppm. A broad singlet was observed for the methyl protons at the 2 nd position of the imidazole ring at d 2.08 and 2.60 ppm, respectively, for both 8a and 8b. A doublet was observed for compound 8b at d 1.82 ppm for three protons of the methyl group in CH(CH 3 )CONH linker. The 1 H NMR spectrum of compound 8e showed a broad singlet for one proton of the CONH amide bond at d 9.83 ppm while another singlet was observed for the hydroxyl proton over phenyl ring at d 9. 
Biological activity
All the compounds were screened for their in vitro antibacterial activity. The results are given in Table III . Among all the series of compounds 2a-e, 5a-d and 8a-f, compounds 8a-f showed a significant degree of activity against all the bacterial strains compared to metronidazole, with compounds 8a, 8d and 8f being the most active. Compound 8b showed significant activity against S. typhi, B. subtilis and S. aureus and the highest activity against E. coli. Compound 8c showed very high activity against E. coli, B. subtilis and S. aureus, but moderate activity against S. typhi.
In the series 5a-d, compound 5c showed considerable activity against B. subtilis while compound 5d showed similar activity against S. typhi. Both of these compounds showed weak to moderate activity against E. coli and S. aureus.
In the series 2a-e, compound 2c showed a significant degree of activity against E. coli and S. aureus and weak activity against the other bacterial strains. Compounds 2b and 2d showed moderate activity against all the strains of bacteria while compound 2a showed a moderate degree of activity against E. coli and S. aureus and weak activity against the other strains of bacteria. However, it was interesting to note that almost all the compounds showed higher or comparable degree of activity compared to metronidazole. All the synthesized compounds were also evaluated for their HIV-1 RT-associated RNA dependent DNA polymerase activity. Compounds 5a, 5b and 5d showed a weak HIV-1 RT inhibitory activity with IC 50 values of 11.9 ± 4.2 µmol L -1 , 19.6 ± 4.8 µmol L -1 and 12.3 ± 3.9 µmol L -1 , respectively (Table IV) . However, all the compounds showed lower activity then efavirenz.
In our study of imidazoles and nitroimidazoles, we found that compounds 5a-d exhibited promising antibacterial activities while showing weak non-nucleosidal reverse transcriptase activity.
Molecular modelling
Based on the fact that among compounds 5a-d, 5d showed relatively high NNRTI activity, we performed in silico docking studies to investigate the interaction of 5d with the NNRTI-binding pocket of the wt HIV-1 RT (PDB entry code 1FK9) using the Extra Precision (XP) mode of the Glide software to gain some structural insight into the interaction of these inhibitors with RT. Validation of the Glide software was carried out by modeling the interaction between efavirenz and HIV-1 RT. Superimposition of the experimental bound (co-crystallized) conformation of efavirenz and that predicted by Glide is shown in Fig. 2 (Fig. 3a) . In case of (S)-5d, it was interesting to note that it made two hydrogen bonds, one hydrogen bond between the basic nitrogen of imidazole and the NH of Lys 101 (Nimidazole … NHLys101 = 2.43 Å) and another hydrogen bond between the -SH and carbonyl oxygen of Val 179 (SH thiophenol … C=O Val179 = 2.05 Å) (Fig. 3b) .
CONCLUSIONS
A number of novel imidazole and nitroimidazole analogs were synthesized with the objective to develop novel anti-HIV agents with broad-spectrum chemotherapeutic properties. The results of anti-HIV and antibacterial activities indicate that 2-methyl-5-nitro-1-{2-[phenyl(thiophen-2-yl)methoxy]ethyl}-1H-imidazole (5a), 2-methyl-5-nitro-1-{2-[1-phenyl-2-(thiophen-3-yl)ethoxy]ethyl}-1H-imidazole (5b), 2-methyl-5-nitro-1-{2-[phenyl(pyrazine-2-yl)methoxy]ethyl}-1H-imidazole (5c) and 2-methyl-5-nitro-1-{2-[phenyl(benzenethiol-2-yl)methoxy]ethyl}-1H-imidazole (5d) revealed moderate antibacterial and weak anti-HIV activity. N-(3-hydroxyphenyl)-2-(substituted imidazol-1-yl) alkanamides (8a-f) also exhibited significant antibacterial activities. It can be concluded that these series of imidazoles and nitroimidazoles might be useful as starting moieties that can be further exploited synthetically for the discovery of analogues with more potent anti-HIV activity with broad-spectrum chemotherapeutic properties.
